Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

医学 红细胞生成 中期分析 艾博汀阿尔法 骨髓增生异常综合症 贫血 国际预后积分系统 补血的 促红细胞生成素 临床试验 内科学 外科 骨髓
作者
Uwe Platzbecker,Matteo Giovanni Della Porta,Valeria Santini,Amer M. Zeidan,Rami S. Komrokji,Jake Shortt,David Valcárcel,Anna Jonášová,Sophie Dimicoli‐Salazar,Ing Soo Tiong,Chien‐Chin Lin,Jiahui Li,Jennie Zhang,Ana Carolina Giuseppi,Sandra Kreitz,Veronika Pozharskaya,Karen L. Keeperman,Shelonitda Rose,Jeevan K. Shetty,Sheida Hayati,Sadanand Vodala,Thomas Prébet,Andrius Degulys,Stefania Paolini,Thomas Cluzeau,Pierre Fenaux,Guillermo Garcia‐Manero
出处
期刊:The Lancet [Elsevier]
卷期号:402 (10399): 373-385 被引量:68
标识
DOI:10.1016/s0140-6736(23)00874-7
摘要

Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but responses are limited and transient. Luspatercept promotes late-stage erythroid maturation and has shown durable clinical efficacy in patients with lower-risk myelodysplastic syndromes. In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-risk myelodysplastic syndromes in the phase 3 COMMANDS trial.The phase 3, open-label, randomised controlled COMMANDS trial is being conducted at 142 sites in 26 countries. Eligible patients were aged 18 years or older, had a diagnosis of myelodysplastic syndromes of very low risk, low risk, or intermediate risk (per the Revised International Prognostic Scoring System), were ESA-naive, and required red blood cell transfusions (2-6 packed red blood cell units per 8 weeks for ≥8 weeks immediately before randomisation). Integrated response technology was used to randomly assign patients (1:1, block size 4) to luspatercept or epoetin alfa, stratified by baseline red blood cell transfusion burden (<4 units per 8 weeks vs ≥4 units per 8 weeks), endogenous serum erythropoietin concentration (≤200 U/L vs >200 to <500 U/L), and ring sideroblast status (positive vs negative). Luspatercept was administered subcutaneously once every 3 weeks starting at 1·0 mg/kg body weight with possible titration up to 1·75 mg/kg. Epoetin alfa was administered subcutaneously once a week starting at 450 IU/kg body weight with possible titration up to 1050 IU/kg (maximum permitted total dose of 80 000 IU). The primary endpoint was red blood cell transfusion independence for at least 12 weeks with a concurrent mean haemoglobin increase of at least 1·5 g/dL (weeks 1-24), assessed in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study treatment. The COMMANDS trial was registered with ClinicalTrials.gov, NCT03682536 (active, not recruiting).Between Jan 2, 2019 and Aug 31, 2022, 356 patients were randomly assigned to receive luspatercept (178 patients) or epoetin alfa (178 patients), comprising 198 (56%) men and 158 (44%) women (median age 74 years [IQR 69-80]). The interim efficacy analysis was done for 301 patients (147 in the luspatercept group and 154 in the epoetin alfa group) who completed 24 weeks of treatment or discontinued earlier. 86 (59%) of 147 patients in the luspatercept group and 48 (31%) of 154 patients in the epoetin alfa group reached the primary endpoint (common risk difference on response rate 26·6; 95% CI 15·8-37·4; p<0·0001). Median treatment exposure was longer for patients receiving luspatercept (42 weeks [IQR 20-73]) versus epoetin alfa (27 weeks [19-55]). The most frequently reported grade 3 or 4 treatment-emergent adverse events with luspatercept (≥3% patients) were hypertension, anaemia, dyspnoea, neutropenia, thrombocytopenia, pneumonia, COVID-19, myelodysplastic syndromes, and syncope; and with epoetin alfa were anaemia, pneumonia, neutropenia, hypertension, iron overload, COVID-19 pneumonia, and myelodysplastic syndromes. The most common suspected treatment-related adverse events in the luspatercept group (≥3% patients, with the most common event occurring in 5% patients) were fatigue, asthenia, nausea, dyspnoea, hypertension, and headache; and none (≥3% patients) in the epoetin alfa group. One death after diagnosis of acute myeloid leukaemia was considered to be related to luspatercept treatment (44 days on treatment).In this interim analysis, luspatercept improved the rate at which red blood cell transfusion independence and increased haemoglobin were achieved compared with epoetin alfa in ESA-naive patients with lower-risk myelodysplastic syndromes. Long-term follow-up and additional data will be needed to confirm these results and further refine findings in other subgroups of patients with lower-risk myelodysplastic syndromes, including non-mutated SF3B1 or ring sideroblast-negative subgroups.Celgene and Acceleron Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
安静落雁完成签到 ,获得积分10
刚刚
1秒前
赵立韶华完成签到,获得积分10
2秒前
Gary发布了新的文献求助10
2秒前
潸潸发布了新的文献求助20
2秒前
彭于晏应助郜雨寒采纳,获得10
2秒前
Q华完成签到 ,获得积分10
4秒前
golfgold发布了新的文献求助10
4秒前
6秒前
眼睛大水蓝完成签到,获得积分10
8秒前
郜雨寒完成签到,获得积分10
8秒前
Hello应助迷路炎彬采纳,获得10
9秒前
13秒前
矮小的寒天完成签到,获得积分10
13秒前
14秒前
无情的菲鹰完成签到,获得积分10
16秒前
小二郎应助JMrider采纳,获得10
17秒前
xhtt发布了新的文献求助10
17秒前
18秒前
18秒前
炙热书白发布了新的文献求助10
19秒前
19秒前
yesss应助xgn采纳,获得50
20秒前
21秒前
霸气的小叮当完成签到,获得积分10
22秒前
rht发布了新的文献求助10
22秒前
Gary完成签到,获得积分10
23秒前
27秒前
Swilder完成签到 ,获得积分10
28秒前
rht完成签到,获得积分20
29秒前
独特夜绿完成签到,获得积分10
34秒前
无足鸟完成签到 ,获得积分10
35秒前
蔡蕾丝完成签到,获得积分10
35秒前
激动的越彬完成签到 ,获得积分10
35秒前
依居发布了新的文献求助20
36秒前
何何何完成签到,获得积分20
39秒前
42秒前
小幸运完成签到,获得积分10
43秒前
科研通AI2S应助何何何采纳,获得10
43秒前
Lucas应助dachengzi采纳,获得10
44秒前
高分求助中
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
Ethnicities: Media, Health, and Coping 700
Development of a new synthetic process for the synthesis of (S)-methadone and (S)- and (R)-isomethadone as NMDA receptor antagonists for the treatment of depression 500
A Dissection Guide & Atlas to the Rabbit 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3089165
求助须知:如何正确求助?哪些是违规求助? 2741290
关于积分的说明 7564290
捐赠科研通 2391558
什么是DOI,文献DOI怎么找? 1268291
科研通“疑难数据库(出版商)”最低求助积分说明 614044
版权声明 598684